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Sir,
We read with great interest the article by Maire et al (2002), who
evaluate the K-Ras mutations in circulating DNA to differentiate
pancreatic cancer from chronic pancreatitis. Based on this, we also
analysed KRAS2 mutations in the serum of 30 patients with
pancreatic cancer and 40 patients with chronic pancreatitis.
Pancreatic cancer patients were staged by means of dynamic
computed tomography, magnetic resonance imaging, and angio-
graphy and/or endoscopic ultrasonography. Diagnosis was histo-
logically confirmed for the patients who underwent surgery.
The diagnosis of chronic pancreatitis was based on the
radiologic data obtained by means of either endoscopic retrograde
cholangiopancreatography or computed tomography.
DNA was extracted from 20ml of the serum by using the QIAmp
Blood Kit (Qiagen) and the mutations in codon 12 of the K-ras
gene were searched as described previously (Jiang et al, 1989).
As positive controls, we used DNA from neoplastic tissues of 10
patients with pancreatic carcinoma by using the DNeasy Tissue Kit
(Qiagen). For molecular analysis, DNA was amplified in the codon
12 region introducing a restriction site (GACCT) for digestion with
BstNl restriction enzyme (PCR-RFLP).
DNA from peripheral blood resulted not mutated in the 40
patients with chronic pancreatitis and in the 30 with pancreatic
carcinoma, while DNA from pancreatic neoplastic tissue resulted
mutated in 70% of the samples.
To verify our results, all the samples were analysed by direct
sequencing using Big Dye terminator v 1.1 cycle sequencing Kit
and performing runs on ABI Prism 310 genetic analyzer (Applied
Biosystem)
Despite what was mentioned in Maire’s article, we failed to find
any mutations in all patients analysed, as well as we failed to
correlate K-ras mutations with the levels of tumour markers such
as Ca 19.9, CA242, CA50, CEA.
The results of the present investigation lead us to these
conclusions: (1) the eventual presence of cancer cells in peripheral
blood may be a rare event, even if numerous reports support the
detection of K-ras abnormalities in the serum, (2) neoplastic cells
are supposed to circulate in clusters, and consequently their
cognition could be hampered by a single blood sample extraction.
(3) Large amounts of nonmutated DNA, coming from leucocytes
held in the buffy coat layer, might also mask some vestiges of the
mutant type of K-ras gene.
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